Greg Yap

Partner at Menlo Ventures

Speaker

Greg, a Menlo Ventures partner, focuses on life science and healthcare investments. He's particularly keen on novel therapeutic platforms, digital health, and transformative technologies. Since 2017, he's led investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, and more. He's also been involved with Benchling, Recursion Pharmaceuticals, and Cofactor Genomics.

Before Menlo, Greg worked at Illumina Ventures as entrepreneur-in-residence, concentrating on genomics-related investments. With over two decades of experience in executive and entrepreneurial roles in life science and digital health, he co-founded startups BlueLight Therapeutics and PyrAmes. At Roche Diagnostics/Ventana, he led a top cancer diagnostic assay business, serving millions of patients and yielding $500 million in annual revenue.

Greg's background includes roles like GE's first healthcare entrepreneur-in-residence, COO at Cellpoint Diagnostics, and VP/GM for genetics and molecular diagnostics at Affymetrix. He was also a McKinsey & Company consultant. He holds a molecular biology degree from Princeton and an MBA from Stanford.

An Aspen Health Innovators Fellow, Greg is actively engaged in the Aspen Global Leadership Network. He graduated summa cum laude from Princeton, and his alma mater is Stanford University’s Graduate School of Business.